Intellia Therapeutics Inc
NTLANASDAQStock · Data from SEC EDGAR 13F · Held by 2 of 87 tracked investors
Intellia Therapeutics Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth52
- Profitability15
- Quality20
- Debt100
- Stability11
- ✓It has more cash than debt.
- ✓Revenue grew 9.1% a year over 3 years.
- ✓The analysts' average target is 88% above the price.
- !The company is loss-making: net profit is negative.
- !In some year revenue fell sharply.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 28.9×
- EV/EBITDA
- -2.9×
Is the company growing?
GrowingRevenue over 3 years grew 9.1% a year. Last year -46.2%.
Does it make money?
Loss-makingNet margin: 0.0%.
Is it financially healthy?
YesChart NTLA
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
2CW Cathie Wood ARK Investment Management | 1.85% |
JS Jim Simons Renaissance Technologies | 0.03% |
Frequently asked questions
How much is Intellia Therapeutics Inc (NTLA) stock?
Intellia Therapeutics Inc shares trade at $12.28, +9.06% over the last trading day. The price is delayed.
What is the market cap of Intellia Therapeutics Inc?
The market cap of Intellia Therapeutics Inc is about $1.7B.
Which big investors hold Intellia Therapeutics Inc?
According to the latest 13F filings, 2 of 87 tracked investors hold Intellia Therapeutics Inc, for example Cathie Wood, Jim Simons.
When will Intellia Therapeutics Inc report its next results?
The next earnings report of Intellia Therapeutics Inc is expected on 5 Nov 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.